Capital Advisors Inc. OK Grows Stake in Pfizer Inc. $PFE

Capital Advisors Inc. OK raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,535,361 shares of the biopharmaceutical company’s stock after purchasing an additional 140,934 shares during the period. Capital Advisors Inc. OK’s holdings in Pfizer were worth $39,121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer during the 2nd quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in Pfizer during the 2nd quarter valued at about $30,000. Finally, True Wealth Design LLC raised its position in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: BMO Capital reaffirmed an Outperform rating and a $30 price target, citing Pfizer’s cost controls and a cautious-but-manageable 2026 outlook — a clear vote of confidence for investors focused on valuation and income. BMO reaffirmation
• Positive Sentiment: Multiple bullish analyst/publication pieces argue Pfizer is undervalued and that its pipeline plus deal-making (Seagen, recent obesity-related buys) position it to recover over time — supporting a value-oriented rally. See Fool’s take on medium-term upside. 2 Predictions for Pfizer in 2026
• Positive Sentiment: Analysts at Zacks raised certain near-term quarterly EPS estimates (Q2 2026/Q2 2027), which can help sentiment around upcoming reports and show some upside to consensus in select periods.
• Neutral Sentiment: In-depth pieces (Seeking Alpha, Yahoo Finance) frame 2026 as a “reset” year: higher R&D and acquisition-driven repositioning (notably the Metsera deal) should strengthen Pfizer’s obesity and oncology lineup, but benefits may take time to show. Pfizer 2026: The Reset Year Why Wall Street Gave Up on Pfizer
• Neutral Sentiment: Market commentary reiterates Pfizer’s cheap forward valuation versus peers and highlights that recent M&A (Seagen, Metsera) is beginning to add revenue and late‑stage assets — a longer‑term positive but not immediate earnings relief.
• Negative Sentiment: Pfizer disclosed a death in a long‑term Hympavzi study after a thrombotic stroke — a safety event that could weigh on that program’s outlook and near‑term sentiment. Hympavzi study death
• Negative Sentiment: Analyst estimate trims and management comments point to earnings pressure from the post‑COVID revenue decline and dilution from acquisitions; Zacks trimmed a Q4 EPS estimate — reinforcing near‑term earnings uncertainty.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PFE. Bank of America dropped their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday. Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.06.

Pfizer Stock Performance

Shares of PFE opened at $25.17 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a 50-day moving average of $25.18 and a two-hundred day moving average of $24.91. The stock has a market cap of $143.13 billion, a P/E ratio of 14.64 and a beta of 0.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.